Robert Schreiber, PhD

Robert Schreiber, PhD

Primary Academic Title

Andrew M. and Jane M. Bursky Distinguished Professor of Immunobiology, Washington University School of Medicine

Research Interest

Biology and signaling of cytokines with special emphasis on IFN-gamma and TNF; role of IFN-gamma in tumor immunity.

Education

  • 1973: PhD, biochemistry and immunology, State University of New York, Buffalo

Training

  • 1973 - : Postdoctoral fellow, medicine and biochemistry, State University of New York, Buffalo
  • 1973 - 1976: Postdoctoral fellow, molecular immunology, Scripps Research Institute, La Jolla, Calif

Selected Research Publications

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy.
  • Sultan H, Takeuchi Y, Ward JP, [...] Schreiber RD
  • Nature 2024
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity.
  • Moynihan KD, Kumar MP, Sultan H, [...] Schreiber RD, [...] Djuretic IM
  • Cancer Discov 2024
TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy.
  • Di Luccia B, Molgora M, Khantakova D, [...] Schreiber RD, [...] Colonna M
  • Sci Immunol 2024
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses.
  • He M, Roussak K, Ma F, [...] Schreiber RD, [...] Klechevsky E
  • Science 2023
Cancer Immunology Research: A Decade of Illumination and Innovation.
  • Schreiber RD, Greenberg PD
  • Cancer Immunol Res 2023
Mechanisms of CD40-dependent cDC1 licensing beyond costimulation.
  • Wu R, Ohara RA, Jo S, [...] Schreiber RD, [...] Murphy KM
  • Nat Immunol 2022

View All Publications